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Abstract
Background: Zinc may act as a neurotransmitter in the central nervous system by activation of the GPR39 metabotropic receptors.
Methods: In the present study, we investigated whether GPR39 knockout would cause depressive-like and/or anxiety-like 
behavior, as measured by the forced swim test, tail suspension test, and light/dark test. We also investigated whether lack of 
GPR39 would change levels of cAMP response element-binding protein (CREB),brain-derived neurotrophic factor (BDNF) and 
tropomyosin related kinase B (TrkB) protein in the hippocampus and frontal cortex of GPR39 knockout mice subjected to the 
forced swim test, as measured by Western-blot analysis.
Results: In this study, GPR39 knockout mice showed an increased immobility time in both the forced swim test and tail 
suspension test, indicating depressive-like behavior and displayed anxiety-like phenotype. GPR39 knockout mice had lower 
CREB and BDNF levels in the hippocampus, but not in the frontal cortex, which indicates region specificity for the impaired 
CREB/BDNF pathway (which is important in antidepressant response) in the absence of GPR39. There were no changes in 
TrkB protein in either structure. In the present study, we also investigated activity in the hypothalamus-pituitary-adrenal 
axis under both zinc- and GPR39-deficient conditions. Zinc-deficient mice had higher serum corticosterone levels and lower 
glucocorticoid receptor levels in the hippocampus and frontal cortex.
Conclusions: There were no changes in the GPR39 knockout mice in comparison with the wild-type control mice, which 
does not support a role of GPR39 in hypothalamus-pituitary-adrenal axis regulation. The results of this study indicate the 
involvement of the GPR39 Zn2+-sensing receptor in the pathophysiology of depression with component of anxiety.
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Introduction
Depression is a leading psychiatric illness, with high morbidity 
and mortality (Ustun, 2004). The lack of appropriate, rapidly acting 
antidepressants is probably due to the direct pathomechanism of 
depression being unknown, and this leads to the high suicide sta-
tistics. Approximately 50% of those diagnosed with major depres-
sive disorder do not respond to antidepressants when using them 
for the first time (Fava et al., 2008). Long-term antidepressant treat-
ment generates many side effects, and more than 30% of depressed 
patients do not experience any mood improvement at all (Fava and 
Davidson, 1996). Until now, only one drug, ketamine, has shown 
rapid action even in treatment-resistant patients (Mathew et  al., 
2012; Lara et al., 2013; Haile et al., 2014). One drug, ketamine, has 
shown rapid and sustained action even in treatment-resistant 
patients (Mathew et al., 2012; Lara et al., 2013; Haile et al., 2014). 
This indicates promise for modulators of the glutamatergic system, 
which may lead to the establishment of homeostasis between glu-
tamate and GABA in the central nervous system (CNS) (Skolnick, 
2002; Skolnick et al., 2009; Malkesman et al., 2012; Pilc et al., 2013; 
Pochwat et al., 2014).  In addition, some trace elements, such as 
magnesium and zinc, are involved in glutamatergic attenuation 
through their binding sites at the N-methyl-d-aspartate (NMDA) 
receptor (Swardfager et al., 2013b). Preclinical findings indicate that 
zinc deficiency has been shown to produce depressive-like behav-
ior (Singewald et al., 2004; Tassabehji et al., 2008; Tamano et al., 2009; 
Whittle et al., 2009; Młyniec and Nowak, 2012; Młyniec et al., 2013a, 
2013b, 2014a). Clinical studies indicate that zinc is lower in the 
blood of depressed people (Swardfager et al., 2013b), and that zinc 
supplementation may produce antidepressant effects alone and in 
combination with conventional antidepressant therapies (Ranjbar 
et al., 2013; Siwek et al., 2013; Swardfager et al., 2013a)..
Zinc is an important trace element in the central nervous sys-
tem and seems to be involved in neurotransmission. As a natural 
ligand, it was found to activate the metabotropic GPR39 recep-
tor (Holst et al., 2007). Highest levels of GPR39 are found in the 
brain regions involved in emotion, such as the amygdala and 
hippocampus (McKee et al., 1997; Jackson et al., 2006). The GPR39 
signals with high constitutive activity via Gq, which stimulates 
transcription mediated by the cyclic adenosine monophosphate 
(cAMP) following inositol 1,4,5-triphosphate turnover, as well as 
via G12/13, leading to activation of transcription mediated by the 
serum response element (Holst et al., 2004). Zinc was found to be 
a ligand capable of stimulating the activity of the GPR39, which 
activates the Gq, G12/13, and Gs pathways (Holst et al., 2007). Since 
zinc shows antidepressant properties and its deficiency leads to 
the development of depression-like and anxiety-like behaviors 
(Whittle et al., 2009; Swardfager et al., 2013a), we investigated 
whether the GPR39 receptor may be involved in the pathophysi-
ology of depression. Recently, we found GPR39 down-regulation 
in the frontal cortex and hippocampus of zinc-deficient rodents 
and suicide victims (Młyniec et al., 2014b). On the other hand, we 
observed up-regulation of the GPR39 after chronic antidepressant 
treatment (Młyniec and Nowak, 2013). In the present study, we 
investigated behavior in mice lacking a GPR39 as well as an hypo-
thalamus-pituitary-adrenal axis (HPA) axis and proteins such as 
CREB, BDNF, and TrkB, all of which are important in the patho-
physiology of depression and the antidepressant response.
Methods
Animals
All of the procedures were conducted according to the 
National Institute of Health Animal Care and Use Committee 
guidelines, which were approved by the Ethical Committee of 
the Jagiellonian University Collegium Medicum, Kraków.
CD-1 male mice (~22 g) were housed with a natural day-night 
cycle, a temperature of 22 ± 2°C and humidity at 55 ± 5%. The 
mice received a zinc-adequate (33.5 mg Zn/kg) or zinc-deficient 
(0.2 mg Zn/kg) diet purchased from MP Biomedicals (France) and 
administered for 6 weeks. The access to food as well as water 
was ad libitum.
GPR39 (−/−) male mice as described by Holst et al. (2009) were 
generated through homologous recombination by Deltagen, Inc. 
by targeting the first exon of GPR39 and replacing the nucleo-
tides from position 278 to 647 of the open reading frame with a 
neomycin-containing cassette. The chimeric males were crossed 
with C57BL/6 females and then backcrossed into C57BL/6 mice. 
The mice were obtained through heterozygous breeding, result-
ing in wild-type (WT), homozygous, or heterozygous littermates. 
Genotypes were verified by polymerase chain reaction. Specific 
primers for the WT and one specific primer for the insert 
sequences were used.
As with the CD-1 mice, the GPR39 knockouts (KOs) were 
housed under standard laboratory conditions. GPR39 KO (−/−) 
and GPR39 WT (+/+) mice received only a standard diet with 
appropriate zinc amounts.
Forced Swim Test
The forced swim test (FST) was carried out on GPR39 KO and 
WT mice. In the classical test described by Porsolt et al. (1977), 
mice were dropped individually into a glass cylinder contain-
ing water. The total duration of immobility after adaptation time 
(the first 2 minutes) was measured during the following 4 min-
utes of the test.
The immobility time in the FST reflects the level of despair 
of the mice, prolonged immobility suggesting depressive-like 
behavior. Because Porsolt et  al. (1977) described FST as being 
a means of evaluating potential antidepressant properties 
of drugs, we prolonged the test, as described by Młyniec et al. 
(2014b), from 4 to 6 minutes, during which time the duration of 
immobility was measured.
Tail Suspension Test
WT and GPR39 KO mice were subjected to the tail suspension 
test (TST) previously described by Mlyniec and Nowak (2012). 
Animals were fastened with medical adhesive tape by the tail 
30 cm below a flat surface and suspended for 6 minutes. During 
this period, the total immobility time was measured. Immobility 
time (when mice hung passively without limb movement) was 
scored manually.
Locomotor Activity
Locomotor activity was measured by photoresistor actometers. 
The number of times the light beams were crossed by GPR39 or 
WT mice was counted by placing them individually in an actom-
eter, with the test duration being between 2 and 8 minutes.
Light/Dark Test
WT and GPR39 KO mice were subjected to the light/dark test as 
previously described by Whittle et al. (2009). The fully automated 
light/dark box apparatus (Stoelting) consisted of white and 
black compartments, which were connected by a small opening 
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located in the center of the common partition. Mice were indi-
vidually placed in the apparatus for 10 minutes and allowed 
to freely explore. The following parameters were quantified in 
the test: 1) time spent in lit compartment (seconds), 2) entries 
into the lit compartment (number), 3)  line crossing (number), 
4) immobility time (seconds), 5) freezing (seconds), and 6) overall 
distance travelled (meters).
Zinc Concentration
The serum zinc concentration in both GPR39 KO and WT mice 
was measured by total reflection X-ray fluorescence as described 
by Młyniec et  al. (2014b). This method is based on the same 
physical principles as energy dispersive X-ray fluorescence. 
Galium was added to the serum sample as an internal standard 
(20 mL) to achieve the final concentration of 5 mg/L. For all meas-
urements, the total reflection X-ray fluorescence spectrometer 
Nanohunter (Rigaku) was used as well as a single measurement 
time of 2000 seconds and a Mo X-ray tube (50 kV, 0.8 mA). The 
detection limits for Zn were about 0.4 mg/L.
Corticosterone Assay
The serum corticosterone concentration was determined by 
a radioimmunological method as described by Młyniec et  al. 
(2013a). Corticosterone was extracted from the serum by eth-
anol. This extract (ethanol-serum) was dried under a nitrogen 
stream and then dissolved in 0.1 mL of 0.05 mM phosphate 
buffer. Extracts were incubated with a 0.1-mL solution of 
1,2,6,7-[3H]-corticosterone and with a 0.1-mL solution of a cor-
ticosterone antibody (Chemicon) for 16 hours at 4°C. Bound and 
free corticosterone were separated using dextran-coated char-
coal. Incubation time for the samples was established for 10 
minutes at 4°C with 0.2 mL of 0.05% dextran and 0.5% charcoal 
suspension. After centrifugation, the supernatant was placed 
in a scintillator. The radioactivity was measured in a counter 
(Beckmann LS 335). The corticosterone content was calculated 
using a log-logit transformation.
Western-Blot Analysis
Glucocorticoid receptor (GR) levels were determined in the fron-
tal cortex and hippocampus of zinc-adequate and -deficient 
mice after administration of the diet for 6 weeks. In the GPR39 
KO and WT mice, in addition to GR, the levels of such proteins 
as CREB, BDNF, and TrkB were also determined, as described by 
Młyniec et al. (2014b). All mice were previously subjected to the 
FST. After rapid decapitation of the mice (24 hours after FST pro-
cedure), tissues were immediately isolated on dry ice and then 
frozen at −80°C until analysis took place.
The frontal cortex and hippocampus were homogenized 
in 2% sodium dodecyl sulphate. After centrifugation, the total 
amount of protein was determined in the supernatant (BCA 
Protein Assay Kit, Pierce Biotechnology). The samples were 
separated using sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (Bio-Rad) under a constant voltage and then 
transferred (in a semi-dry transfer process) to nitrocellulose 
membranes. To avoid nonspecific binding, membranes were 
blocked for 60 minutes at room temperature with blocking solu-
tion (Roche). Then the membranes were incubated overnight 
at 4°C with primary antibodies: anti-GR (1/1000, Santa Cruz 
Biotechnology), anti-CREB (1/1000), anti-BDNF (1/1000), and 
anti-TrkB (1/400) (Abcam, Cambridge, UK). After washing (3 × 10 
minutes in Tris-buffered saline with Tween 20), the membranes 
were incubated in a secondary antibody with a horseradish per-
oxidase-conjugated anti-mouse or anti-rabbit immunoglobulin 
G (Western Blotting Kit, Roche) for 60 minutes at room tempera-
ture. Blots were developed using an enhanced chemilumines-
cence reaction (BM Chemiluminescence Western Blotting Kit, 
Roche). The GR, CREB, BDNF, and TrkB signals were visualized 
and quantified with the Gel Doc XR+ system and Image Lab 4.1 
software (both Bio-Rad). To confirm equal loading of the sam-
ples on the gel, the membranes were incubated with a loading 
control antibody and then processed as described above. The 
density of each GR, CREB, BDNF, or TrkB protein band was nor-
malized to the density of the loading control band.
Statistical Analysis
The data are presented as the mean ± SEM and were evaluated 
with the Student t test using GraphPad Prism software (San 
Diego, CA). P < .05 was considered to be statistically significant.
Results
Behavioral Studies of Gpr39 KO Mice
Before experiments, mice were weighed. There were no differ-
ences between WT and GPR39 KO groups [t(10) = 0.2715, P = .7916].
The effect of deletion of the GPR39 on immobility time 
in the FST is shown in Figure 1A. GPR39 KO mice showed an 
increased immobility time in the FST designed by Porsolt et al. 
Figure 1. The effect of GPR39 knockout (KO) on immobility time in the standard (A) and prolonged (B) forced swim test in GPR39 KO mice. Values are the means ± SEM 
of 6 to 7 animals per group. * p < 0.05, ** p < 0.001 vs wild-type control.
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(1977) in comparison with WT mice [t(15) = 2.563, P = .0217]. 
We found a more significant increase in immobility time in 
GPR39 KO vs WT using a modified FST (Młyniec et al., 2014b) 
[t(15) = 4.571, P = .0004] (Figure 1B). We also found an increased 
immobility time in the TST in GPR39 KO mice [t(10) = 2.415, 
P = .0363] (Figure 2).
There were no differences in locomotor activity between 
GPR39 KO and WT mice after 2 [t(15) = 0.004016, P = .9968], 
4 [t(15) = 0.1016, P = .9205], 6 [t(15) = .04298, P = .9663], and 8 
[t(15) = 0.05586, P = .9562] minutes (Table 1).
In the light/dark box test, GPR39 KO mice displayed decreased 
entries into the lit compartment, line crossing, and enhanced 
immobility time compared with WT control mice (Table 2).
Serum Zinc Concentration in GPR39 KO Mice
There was no difference between GPR39 KO (1.707 ± 0.1606 mg/L) 
and WT mice (1.848 ± 0.1130 mg/L) in terms of serum zinc con-
centration [t(11) = 0.7328, P = .4790].
CREB, BDNF, and TrkB Protein Levels in GPR39 
KO Mice
The effect of deletion of the GPR39 on CREB, BDNF, and TrkB lev-
els in mice is shown in Figure 3. GPR39 KO mice show reduced 
CREB levels in the hippocampus [t(12) = 2.427, P = .0319] but not 
in the frontal cortex [t(12) = 0.8192, P = .4286] in comparison with 
WT mice (Figures 3A and D, respectively).
In a similar way to the CREB levels, GPR39 KO mice also 
have reduced BDNF levels in the hippocampus [t(10) = 2.510, 
P = .0309] (Figure 3B), but not in the frontal cortex, in compari-
son with WT control mice [t(12) = 0.6015, P = .5587] (Figure 3E). 
There was no difference in TrkB levels between GPR39 KO 
and WT mice in the hippocampus [t(12) = 0.6861, P = .5057] 
or frontal cortex [t(12) = 0.9219, P = .3747] (Figure  3C and F, 
respectively).
Serum Corticosterone Concentration in Zinc-
Deficient and GPR39 KO Mice
The effects of zinc deficiency on the serum corticosterone level 
are shown in Figure 4A. A 6-week zinc-deficient diet causes a 
significant increase in serum corticosterone concentration in 
comparison with control mice [t(8) = 2.547, P = .0343]. There were 
no significant differences between GPR39 KO and WT [t(9) = 1.298, 
P = .2266] (Figure 4B).
GR Protein Levels in Zinc-Deficient and GPR39 
KO Mice
Administration of a zinc-deficient diet for 6 weeks causes a 
reduction in glucocorticoid receptor levels in the hippocampus 
[t(11) = 2.649, P = .0226] and frontal cortex [t(12) = 2.475, P = .0292] 
(Figure 5A and B, respectively). There were no changes in the GR 
levels in the hippocampus [t(12) = 0.3628, P = .7231] or the frontal 
cortex [t(12) = 0.4638, P = .6511] of GPR39 KO mice in comparison 
with WT control mice (Figure 5C and D, respectively).
Discussion
In the present study, we found that elimination of GPR39 leads 
to the development of depressive-like behavior, as measured by 
the FST and TST. Additionally, we found decreased entries into 
the lit compartment and line crossing and increased immobil-
ity time in the light/dark test, indicating anxiety-like phenotype 
in GPR 39 KO mice. Although not statistically significant, we 
also observed some tendencies towards less time spent in the 
lit compartment (decreased by 17%) and increased and freezing 
behavior (28%) in GPR39 KO compared to WT mice.
The GPR39 was found to be activated by zinc ions (Holst 
et al., 2007; Yasuda et al., 2007), and the link between zinc and 
depression is well known (Maes et  al., 1997, 1999; Szewczyk 
et al., 2011; Swardfager et al., 2013a, 2013b). Ishitobi et al. (2012) 
did not find behavioral abnormalities in the FST after adminis-
tering antisense of DNA for GPR39-1b. In our present study, mice 
with general GPR39 KO were used. GPR39-1a full-length isoform 
was found to be a receptor for zinc ions, whereas GPR39-1b, cor-
responding to the 5-transmembrane truncated form (Egerod 
et al., 2007), did not respond to zinc stimulation, which means 
that the GPR39-1b splice variant is not a receptor of Zn2+ (Yasuda 
and Ishida, 2014).
Activation of the GPR39 triggers diverse neuronal path-
ways (Holst et  al., 2004, 2007; Popovics and Stewart, 2011) 
that may be involved in neuroprotection (Depoortere, 2012). 
Zinc stimulates GPR39 activity, which activates the Gαs, Gαq, 
and Gα12/13 pathways (Holst et  al., 2007). The Gαq pathway 
triggers diverse downstream kinases and mediates CREB 
activation and cyclic adenosine monophosphate response 
element-dependent transcription. Our previous study showed 
decreased CREB, BDNF, and TrkB proteins in the hippocampus 
of mice under zinc-deficient conditions (Młyniec et al., 2014b). 
Moreover, disruption of the CaM/CaMKII/CREB signaling path-
way was found after administration of a zinc-deficient diet for 
5 weeks (Gao et al., 2011). Since GPR39 was discovered to be a 
receptor for zinc, we previously investigated whether GPR39 
may be involved in the pathophysiology of depression and 
suicide behavior. In our postmortem study, we found GPR39 
down-regulation in the hippocampus and the frontal cortex 
of suicide victims (Młyniec et al., 2014b). In the present study, 
we investigated whether GPR39 KO would decrease levels of 
Figure 2. The effect of GPR39 knockout (KO) on immobility time in the tail sus-
pension test in GPR39 KO mice. Values are the means ± SEM of 6 animals per 
group. p* < 0.05 vs wild-type control.
Table 1. The Effect of GPR39 KO on Spontaneous Locomotor Activity 
in GPR39 KO Mice. Values are the means ± SEM of 6 to 7 animals per 
group.
2 min 4 min 6 min 8 min
WT 158.1 ± 15.08 307.8 ± 24.42 458.5 ± 29.09 609.3 ± 35.23
GPR39 KO 158.2 ± 18.45 311.9 ± 31.65 456.5 ± 39.81 605.9 ± 47.21
D
ow
nloaded from
 https://academ
ic.oup.com
/ijnp/article-abstract/18/3/pyu002/701468 by guest on 08 April 2020
Młyniec et al. | 5
such proteins as CREB, BDNF, and TrkB, which were also found 
to be impaired in depression in suicide victims (Dwivedi et al., 
2003; Pandey et al., 2007). Indeed, we found that lack of the 
GPR39 gene causes CREB and BDNF reduction in the hip-
pocampus, but not in the frontal cortex, suggesting that the 
hippocampus might be a specific region for CREB and BDNF 
down-regulation in the absence of a zinc receptor. The CA3 
region of the hippocampus seems to be strongly involved in 
zinc neurotransmission. Besser et  al. (2009) found that the 
GPR39 is activated by synaptically released zinc ions in the 
CA3 area of the hippocampus. This activation triggers Ca2+ 
and Ca2+/calmodulin kinase II, suggesting that it has a role 
in neuron survival/neuroplasticity in this brain area (Besser 
et al., 2009), which is of importance in antidepressant action. 
In this study, we did not find any changes in TrkB levels in 
either the hippocampus or frontal cortex; in the case of the 
hippocampus, this may be a compensatory mechanism, and 
it needs further investigation.
Table 2. Behavioral Parameters Quantified in the Light/Dark Test in WT and GPR 39 KO mice. Values are the means ± SEM of 6 animals per group. 
*p < 0.05, **p < 0.01 vs proper control.
Wild type GPR39 knockout Statistics
Time spent in lit compartment (s) 300.5 ± 30.47 249.0 ± 26.24 [t(10) = 1.281, p = 0.2291]
Entries into the lit compartment (number) 18.67 ± 1.978 13.17 ± 0.543 * [t(10) = 2.628, p = 0.0230]
Line crossing (number) 41.17 ± 2.713 25.67 ± 1.116 ** [t(10) = 5.284, p = 0.0004]
Immobility time (s) 103.5 ± 15.86 146.9 ± 10.42 * [t(10) = 2.287, p = 0.0452]
Freezing (s) 128.0 ± 12.95 164.3 ± 11.03 [t(10) = 2.130, p = 0.0590]
Overall distance travelled (m) 23.75 ± 2.049 23.42 ± 1.540 [t(10) = 0.131, p = 0.8982]
Figure 3. The effect of GPR39 knockout (KO) on CREB, BDNF, and TrkB levels in the hippocampus (A, B, and C, respectively) and in the frontal cortex (D, E, and F, respec-
tively) of GPR39 KO mice. Values are the means ± SEM of 6 to 7 animals per group. *p < 0.05 vs wild-type control.
Figure 4. The effect of a zinc-deficient diet (A) or GPR39 knockout (B) on serum corticosterone level in mice. Values are the means ± SEM of 6 to 7 animals per group. 
*p < 0.05 vs proper control.
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There is strong evidence that zinc deficiency leads to hyper-
activation of the HPA axis (Watanabe et  al., 2010; Takeda and 
Tamano, 2012; Młyniec et al., 2012, 2013a), which is activated as 
a reaction to stress. The activity of the HPA axis is regulated by 
negative feedback through GR receptors that are present in the 
brain, mainly in the hippocampus (Herman et  al., 2005). This 
mechanism was shown to be impaired in mood disorders. In 
the present study, we compared corticosterone and GR receptor 
levels in zinc-deficient and GPR39 KOs. We found an elevated 
corticosterone concentration in the serum and decreased GR 
levels in the hippocampus and frontal cortex of mice receiving 
a zinc-deficient diet. However, there were no changes in corti-
costerone or GR levels in GPR39 KO mice in comparison with WT 
mice. This suggests that the depressive-like behavior observed 
in mice lacking the GPR39 gene is not due to higher corticoster-
one concentrations and that there is no link between GPR39 and 
the HPA axis. In the present study, we did not find any changes 
in the serum zinc level in GPR39 KO mice in comparison with 
WT mice, which indicates a possible correlation between serum 
zinc and serum corticosterone.
Depressive-like changes with component of anxiety observed 
in GPR39 KO mice may result of glutamatergic abnormalities that 
were found in cases of zinc deficiency, but this requires further 
investigation. Zinc as an NMDA antagonist modulates the gluta-
matergic system, which is overexcited during depression. Zinc 
co-released with glutamate from “gluzinergic” neurons modu-
lates excitability of the brain by attenuating glutamate release 
(Frederickson et al., 2005). The GPR39 zinc receptor seems to be 
involved in the mechanism regulating the amount of glutamate 
in the brain (Besser et al., 2009). Activation of the GPR39 up-reg-
ulates KCC2 and thereby enhances Cl− efflux in the postsynaptic 
neurons, which may potentiate γ-aminobutyric acidA-mediated 
inhibition (Chorin et al., 2011).
Our present study shows that deletion of GPR39 leads to depres-
sive-like behaviors in animals, which may be relevant to depressive 
disorders in humans. Decreased levels of CREB and BDNF proteins 
in the hippocampus of GPR39 KO mice support the involvement of 
GPR39 in the synthesis of CREB and BDNF, proteins that are impor-
tant in neuronal plasticity and the antidepressant response.
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